Abiomed's slows patient enrolment in artificial heart trial:
This article was originally published in Clinica
Executive Summary
Abiomed, of Danvers, Massachusetts, has said that despite slowing the rate of patient enrolment for a human trial of its fully-implantable artificial heart, AbioCor, the firm expects to seek FDA approval for the device by the end of 2003. The delay in enrolment is reported to be due to Abiomed focusing on identifying and addressing potential problems in order to maximise the clinical success with the nine remaining AbioCor devices awaiting implantation.